Deutsche Bank initiated coverage of Inari Medical with a Buy rating and $68 price target. Inari is market leader in mechanical thrombectomy to address dangerous blood clots in patients with venous thromboembolisms, the analyst tells investors in a research note. The firm expects mechanical thrombectomy technology penetration to move steadily higher over the next several years, yielding “robust” revenue growth through 2030 for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical price target lowered to $63 from $65 at Baird
- Inari Medical price target lowered to $55 from $60 at Truist
- Inari Medical price target raised to $71 from $55 at Canaccord
- Inari Medical price target lowered to $65 from $84 at Wells Fargo
- Inari Medical Announces CFO Transition and Executive Compensation